Drug intelligence / Profile preview

ZL-1101

Development stage: Preclinical
Lead developer: UCB
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

**ZL-1101** is a first-in-class anti-OX40 antagonistic monoclonal antibody developed for the treatment of autoimmune diseases. It inhibits OX40 signaling, suppressing lymphocyte activation, cellular proliferation, and production of inflammatory cytokines, as demonstrated in in vitro and in vivo inflammatory and autoimmune disease models. Zai Lab licensed exclusive worldwide rights from UCB in 2015, with plans to file an IND application in 2018 targeting conditions such as graft-versus-host disease (GVHD) and systemic lupus erythematosus (SLE).[1][3][4][7]

Targets

CD28 (Cluster of Differentiation 28)

Beyond the preview

Go deeper on ZL-1101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ZL-1101.

Explore the full profile